XR9051
XR9051 is an orally active and specific modulator of P-glycoprotein-mediated multidrug resistance (MDR).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 762219-35-2
- Formule: C39H38N4O5
- Masse moléculaire:642.74
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-50879
Elacridar
-
HY-10550
Tariquidar
-
HY-15255
Zosuquidar
-
HY-50671
Zosuquidar trihydrochloride
-
HY-13646
Encequidar
-
HY-108347
CP-100356 hydrochloride
-
HY-50879R
Elacridar (Standard)
-
HY-17013
Dofequidar
-
HY-13646A
Encequidar mesylate
-
HY-10550A
Tariquidar methanesulfonate, hydrate
-
HY-13574A
Biricodar
-
HY-15134
ONT-093
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| EMT6 | IC50 |
220 nM
Compound: 1 (XR-9051)
|
Reversal effect on the accumulation of [3H]- daunorubicin in mouse mammary carcinoma cell line EMT6/AR 1.0
Reversal effect on the accumulation of [3H]- daunorubicin in mouse mammary carcinoma cell line EMT6/AR 1.0
|
[PMID: 10098671] |
XR9051 is able to reverse resistance to a variety of cytotoxic drugs, including doxorubicin, etoposide and vincristine, which are associated with classical MDR[1].
XR9051 is highly active and gave at least a 15- to 20- fold decrease in the doxorubicin IC50, in the acquired resistance cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 762219-35-2
-
Masse moléculaire 642.74
-
Formule C39H38N4O5
-
SMILES
O=C(NC1=CC=C(CCN2CC3=C(C=C(OC)C(OC)=C3)CC2)C=C1)C4=CC=CC(/C=C(C(N(C)/C5=C\C6=CC=CC=C6)=O)\NC5=O)=C4
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. I L Dale , et al. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. Br J Cancer. 1998 Oct;78(7):885-92. [Content Brief]
[2]. P Mistry, et al. In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance. Br J Cancer. 1999 Apr;79(11-12):1672-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
XR9051 Related Classifications
HY-13776 Related Classifications
Powered by Bioz